CRISPR And Cas Genes Market Analysis Report By Product & Service, By Application, By End Use, By Region And Segment Forecasts From 2021 To 2028

Report ID: MN17620253  |  Published: July 2021  |  No of Pages: 220
Format: Electronic (PDF)  |  Industry: Biotechnology


The global CRISPR and Cas genes market was prized by USD 1.5 billion in 2020. It is estimated to witness a 21.7% CAGR from 2021 to 2028.


Since the Nobel Prize in Chemistry was accepted by Jennifer A. Doudna and Emmanuelle Charpentier in support of the inventive investigation in CRISPR/Cas9 genetic scissors for genome editing. It absolutely influenced the market for CRISPR and Cas genes, in 2020. It was an extraordinary year.


Moreover, the growth of CRISPR-sourced analytical investigation, to deal with the timeline, in addition to sample compilation challenges for Covid-19 viewing, is propelling the market growth. The experiments are intended to offer compensations like portability, fast discovery, no necessity of particular laboratory apparatus, and exceptional accuracy plus sensitivity. For example, the investigators of Gladstone Institutes, built on a CRISPR-sourced analysis that utilizes smartphones to distribute outcomes, in December 2020.

Application Insight

In 2020, the biomedical applications sector held the biggest 92.8% revenue share and led the CRISPR and Cas genes market. The growing execution of CRISPR gene-editing tools, in several sections of biomedical sciences, has, mainly, added to the extraordinary revenue of this section. A wide-ranging study, in the biomedical area, is estimated to impel the expansion of the sector, during the forecast period.

Besides, the execution of nano-carriers, as well as the presentation of enhanced deliverance method, has, considerably, improved the effectiveness, in addition to the specificity of this expertise.

In addition, the integration of modern breeding technology has given rise to enhancements in farming production. Latest advancements in technology have facilitated harvest development via permitting incompetently targeted alterations, in nearly all of the crops.

Due to the numerous compensations like enhanced shelf life, augmented the ability of the resistance to climatic alterations, the use of this expertise in the farming domain is estimated to augment, during the approaching years

Product and Services Insight

The product sector held the major 79.4% revenue share, in 2020 and led the CRISPR-associated Cas genes market. The existence of CRISPR gene editing kits and new tools designed for gene alteration experimentation speaks to the rising insistence on genome editing resolution.

The appearance of new functions, together with increasing funds for the gene-editing sourced R&D actions are, furthermore, anticipated to impel the market. For example, the use of DNA-free Cas9, particularly in tobacco, apple protoplasts, rice lettuce, and grapevine, is estimated to maintain the expected enlargement, during the near future.

Since a lot of researchers, operational on gene editing, are taking on these products, this section of the market is anticipated to produce superior revenue, during the forecast period. In contrast, cell line engineering services are mainly the widespread services, offered by CRISPR-based gene editing companies. The companies are powering this expertise to engineer an extensive variety of CRISPR cell line representation, by several genes otherwise locus precise alterations.

End-Use Insight

The biotechnology & pharmaceutical companies sector held a 48.8% revenue share, in 2020, and led the CRISPR and Cas genes market.


The pharmaceutical companies are, progressively more, taking on the CRISPR-Cas9 to make superior biological models used for the human sicknesses, in a lesser amount of time and additionally speed up the recognition & corroboration of the latest remedial goals. Therefore, the existence of a vast clinical pipeline, rooted in the CRISPR gene-editing expertise, is anticipated to increase the enlargement of the market.

Regional Insight

In 2020, North America held the biggest 38.4% revenue share and dominated the global CRISPR and Cas genes market. The increasing biopharmaceutical R&D activities along with the operational engagement of the diverse pharmaceutical companies in the improvement of new treatments via applying genome editing tools has, considerably, added to the supremacy of the region. Likewise, the U.S. possesses the biggest amount of CRISPR publications, symbolizing wide-ranging research, within the region.

The market for CRISPR And Cas Genesis is expected to observe the highest enlargement, all through the forecast period, in the Asia Pacific. This can be credited to the rising figure of continuing clinical trials as well as growing exploration in gene-editing tools, within the region. Besides, the rising recognition of CRISPR technology, in Asian nations like Japan and China, is anticipated to, additionally, encourage the expansion of the market, within the region.


Due to the expanded functional backdrop and the technical progressions, the market is observing a bigger rivalry. This has prompted the admission of other companies in this field which is, additionally, raising the rivalry. These companies are working together with international companies, to build on innovative product lines and improve their attendance in the market.

Some of the companies for the CRISPR and Cas genes market are:

    • Recombine tics, Inc.
    • Hera Bio Labs
    • Cibus
    • Mammoth Biosciences
    • Thermo Fisher Scientific, Inc.
    • Intellia Therapeutics, Inc.
    • Lonza
    • Danaher Corporation
    • Horizon Discovery Group plc
    • eGenesis
    • Cellectis, CRISPR Therapeutics
    • Add gene
    • OriGene Technologies, Inc.
    • Vertex Pharmaceuticals Incorporated
    • Beam Therapeutics
    • Inscripta, Inc.
    • Synthego
    • Takara Bio Inc.
    • Merck KGaA
    • Intellia Therapeutics, Inc.
    • GenScript
    • F. Hoffmann-La Roche Ltd.
    • Editas Medicine, Inc.
    • Caribou Biosciences, Inc.
    • AstraZeneca plc.

 Report Scope

Report Attribute


The market size value in 2021

USD 2.1 billion

The revenue forecast in 2028

USD 7.4 billion

Growth Rate

CAGR of 21.7% from 2021 to 2028

The base year for estimation


Historical data

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD Million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segment covered

Product and service, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; France; Italy; Spain; U.K.; China; Japan; South Korea; India; Brazil; Mexico; South Africa; Saudi Arabia

Companies profiled

AstraZeneca plc.; Addgene; Caribou Biosciences, Inc.; Cellectis; CRISPR Therapeutics; Editas Medicine, Inc.; eGenesis; F. Hoffmann-La Roche Ltd.; Horizon Discovery Group plc; GenScript; Danaher Corporation; Intellia Therapeutics, Inc.; Lonza; Merck KGaA; Intellia Therapeutics, Inc.; Takara Bio Inc.; Thermo Fisher Scientific, Inc.; Synthego; Mammoth Biosciences; Inscripta, Inc.; Cibus; Beam Therapeutics; PLANTeDIT; Vertex Pharmaceuticals Incorporated; Hera BioLabs; OriGene Technologies, Inc.; Recombinetics, Inc.

Customization scope

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For this study, Million Insights has segmented the global CRISPR and Cas genes market report based on product and service, application, end-use, and region:

• Product & service Outlook (Revenue, USD Million, 2017 - 2028)
    • By Product
        • Kits & Enzymes
            • Vector-based Cas
            • DNA-free Cas
        • Libraries
        • Design Tool
        • Antibodies
        • Others
    • By Service
        • Cell Line Engineering
        • gRNA Design
        • Microbial Gene Editing
        • DNA Synthesis

• Application Outlook (Revenue, USD Million, 2017 - 2028)
    • Biomedical
        • Genome Engineering
        • Disease Model Studies
        • Functional Genomics
        • Epigenetics
        • Others
    • Agricultural

• End-use Outlook (Revenue, USD Million, 2017 - 2028)
    • Biotechnology & Pharmaceutical Companies
    • Academics & Government Research Institutes
    • Contract Research Organizations (CROs)

• Regional Outlook (Revenue, USD Million, 2017 - 2028)
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • France
        • Italy
        • Spain
        • U.K.
    • The Asia Pacific
        • China
        • Japan
        • India
        • South Korea
    • Latin America
        • Brazil
        • Mexico
    • Middle East & Africa
        • South Africa
        • Saudi Arabia

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
Connect With Expert
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service

Get a Free Sample

FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...